New hope for kids with MS: testing Easier-to-Take pills

NCT ID NCT07483632

Not yet recruiting Disease control Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Mar 25, 2026 · Last updated Apr 17, 2026 · Updated 3 times

Summary

This study aims to test the safety and effectiveness of two oral medications, diroximel fumarate (DRF) and dimethyl fumarate (DMF), for treating children with relapsing forms of multiple sclerosis (MS). It will involve about 185 children and teens, comparing the new pills to an existing MS drug called fingolimod over two years. The main goals are to see which treatment causes fewer side effects and is better at preventing MS relapses and new brain lesions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.